Digital Therapies

EVERSANA™ adds powerful predictive analytics platform with HVH Precision Analytics acquisition | PR Newswire | 7/15/2020

… actions for EVERSANA clients. The fit is seamless, and we are onboarding new programs right now,” said Steve Costalas , CEO, HVH Precision Analytics. EVERSANA, which is currently managing the launch of multiple pharmaceutical and digital therapies , offers a fully integrated commercial services platform designed to solve global pricing, access, reimbursement, adherence and product delivery challenges in the life science sector. “Combining HVH technologies with EVERSANA’s full commercial services puts prediction …

Swedish Pharma company Orexo rolls out digital therapeutic for depression, alcohol use disorder | MobiHealthNews | 7/13/2020

… 19 pandemic has created barriers to in-person care, many are pitching technology as a way to help reach individuals in their home. “Due to the COVID-19 pandemic, the need for clinically validated digital therapies is unprecedented. This pressing need, combined with the FDA’s measures to expand availability of digital therapies for psychiatric disorders, have accelerated launch plans for Orexo’s digital offering,” Nikolaj Sørensen, president and CEO of Orexo …

Follow Digital Therapies:    

Orexo Launches Deprexis® and Vorvida® in the US and Provides Updated Financial Guidance | PR Newswire | 7/2/2020

UPPSALA, Sweden Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY ) announces today the US launch of the scientifically proven digital therapies deprexis ® and vorvida ® , for treatment of symptoms of depression and management of problematic alcohol misuse respectively. deprexis ® is available to patients from July 1 st and vorvida ® from July 15 th . The decision to accelerate the launch is based on the patient need for access to low-risk clinically-validated …

Orexo Launches Deprexis(R) and Vorvida(R) in the US and Provides Updated Financial Guidance | 7/2/2020

News Release - July 2, 2020 Orexo Launches Deprexis(R) and Vorvida(R) in the US and Provides Updated Financial Guidance FDA’s “Enforcement Policy” and Orexo’s strong financial position enable investments in an accelerated commercialization of its scientifically proven digital therapies Preliminary estimated sales potential of USD 420-650 million for the DTx portfolio five years post launchTo enable accelerated launch of all three products investments will increase and OPEX for FY 2020 …

Positive Results from Human PK Study Assessing Orexo’s Intranasal Nalmefene Formulations for Opioid Overdose Reversal | PR Newswire | 6/30/2020

… to USD 1.5-2 billion. The combined estimated sales potential for OX125 and OX124 amounts to USD 110-170 million five years post launch, where the majority refers to OX124. About Orexo Develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental health. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American …

Medtech assessor Elektra Labs is offering free evaluations of COVID-19 biosensors to doctors | TechCrunch | 6/29/2020

… the validation, usability, utility, security and data governance components of connected sensor and it actually published the methodology behind its scoring framework in Nature Digital Medicine earlier this year. No one knows how effective digital therapies are, but a new tool from Elektra Labs aims to change that Backed by venture capital firms including Founder Collective, Boost VC, Lux Capital, Maverick Ventures, Village Global and Arkitekt Ventures, the early-stage …

Demand for digital mental health solutions can increase post-pandemic, says GlobalData | 6/26/2020

… tech driven platforms like BioBeats, which use artificial intelligence (AI) and wearables to provide mental health support to big-name wellness-based solutions like Headspace and Calm. Alongside these are online services like ICS Digital Therapies , which work as an intermediary to allow traditional talking therapies like cognitive behavioral therapy (CBT) and long-term counselling to take place virtually. The big question for organisations in all three of these categories …

Partnership for the Clinical Validation of Textile Computing Solutions | 6/24/2020

… that leverages the Myant Platform, the company’s core textile computing technology (commercially known as Skiin), as well as research from KITE and UHN to develop and clinically validate an array of digital diagnostics and digital therapies backed by the Myant Platform. These solutions point to a new mode of care delivery that addresses the fundamental distribution and adoption challenges that limit existing telehealth systems. The solutions–ranging from continuous and …

Kaia Health gets $26M to show it can do more with digital therapeutics – TechCrunch | 6/18/2020

… And it also helps to get more credibility as an industry.” Kaia retired an earlier direct consumer subscription strand of its business to focus fully on b2b — chasing the “holy grail” of having its digital therapies fully reimbursed via users’ medical insurance. Though it does still offer a number of free apps for consumers, with a physical trainer type function, as a way to gather movement data to feed its …

Kaia Health plans expansion into virtual care for COPD with $26M in new funding - MedCity News | 6/18/2020

… the acceleration of telehealth during the Covid-19 pandemic had also driven interest in its work. “We are excited by the opportunity to drive our business forward given heightened awareness of the merits of digital therapies among payers, companies, care providers and consumers, and the growing importance of delivering care in the home. We believe we are on the precipice of moving our solutions from the early adopter set to …

Orexo and Lyfebulb Announce Call for Digital Solutions to Treat Substance Use Disorder | PR Newswire | 6/17/2020

UPPSALA, Sweden , June 17, Orexo, a Swedish pharmaceutical company focused on improved pharmaceuticals and digital therapies , and Lyfebulb, a patient empowerment platform, announced that the Lyfebulb-Orexo Innovation Challenge: Digital Therapeutics for Substance Use Disorder is now accepting applications. The goal of the initiative is to seek novel digital solutions, in early stages of development, to address unmet needs in supporting successful, long-term recovery from alcohol and opioid use …

Digital healthcare is all the rage in Covid-19 times. But not everyone is invited to the party | Fortune | 6/17/2020

… onset of the pandemic, the pre-revenue health tech company struggled to raise additional funding and furloughed the majority of its employees for two weeks in November, per CNBC —highlighting the issue of integrating digital therapies within the existing hierarchy (think pharmaceutical companies, regulators, and insurers). An important licensing agreement with Otsuka Pharmaceuticals meanwhile fell apart earlier this year . The coronavirus, the company says, only made matters worse. “The onset …

AptarGroup, Sonmar Partner on Digital Platform for Respiratory-Related Therapies | 6/16/2020

Collaboration also includes strategic investment by Aptar Pharma; will develop digital therapies and services targeting respiratory diseases, Business Wire 06.15.20 AptarGroup Inc. , a global leader in consumer dispensing, active packaging and drug delivery solutions and services, and Sonmol , a leading Chinese digital respiratory therapeutics company, have announced a collaboration for developing a digital therapies and services platform targeting respiratory and other diseases. This collaboration will initially focus on bringing together …

The Future Of Space-Age Digital Therapeutics (infographic) | 4/3/2020

… of treatment for many of the toughest cases out there. Digital Therapeutics involves interventions driven by tech and software programs, with applications in treating both physiological and neurobehavioral conditions. When combined with conventional treatments digital therapies improve outcomes, explore new options to meet unaddressed needs, and could reduce the necessity of medications overall or at the very least support the efficacy of said medications. The scope of the implementation in …

‘This is healthcare’s Amazon moment’: Dr. Stephen Klasko’s 5 predictions on healthcare delivery post-COVID-19 | Becker’s Hospital Review | 4/1/2020

… ceding to mass personalization and rentable scale, hospitals will need to adapt to the ‘new normal’ of costly ‘sick care’ giving way to affordable, personalized and preemptive care with genomics, sensors and AI based digital therapies ,” said Dr. Klasko. “For providers that do not have a payer component, there will need to be new partnerships and creative alignments with traditional payers for either to survive.” 2. The combination of increased …

The promise of digital therapeutics | 3/31/2020

… healthcare, is evolving the regulatory framework accordingly. A glance at some of the start-ups with products coming to market gives a sense of the variety of approaches to healthcare problems that these new digital therapies are utilizing. Products include video games to treat mental- and behavioral-health issues; a digital therapeutic platform that incorporates neurological music therapy, sensors, and artificial intelligence (AI) to help patients who have suffered a …

Some optimism for the post-COVID healthcare system | Modern Healthcare | 3/30/2020

… happy lives without healthcare getting in the way. The idea of “health assurance” recognizes that costly “sick care” will give way to affordable, personalized and preemptive care with genomics, sensors and artificial intelligence-based digital therapies . We should never again use the word “telehealth” just as we don’t use the word “telebanking.” It’s just that 90% of banking went from the bank to the home. Much the same will happen …

Orexo Publishes the Annual Report for 2019 | PR Newswire | 3/26/2020

… information within this field. Orexo will continue to assess the situation and will be providing a further update in the Q1 report scheduled on April 28 , 2020. About Orexo Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs mainly within the growing space of addiction. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone …

Orexo Has Repurchased 14 Percent of Own Corporate Bonds | PR Newswire | 3/25/2020

… of the cash balance is kept in US dollar. Following the purchase, Orexo’s holding of its unsecured corporate bonds amounts to a nominal amount of SEK 40,500,000 . About Orexo Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs mainly within the growing space of addiction. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone …

EVERSANA™ appoints digital therapeutics pioneer Ed Cox to lead global commercialization platform for digital medicine | PR Newswire | 3/18/2020

… we have the opportunity to directly impact the two critical questions facing the fields of digital medicine and digital therapeutics: how can companies directly commercialize these products, and how can pharmaceutical companies effectively deploy digital therapies into their product portfolios to maximize the value and impact,” said Cox. Cox has served as chairman of the first digital therapeutics conferences, including DTxDM ( San Jose, CA ) and DTx East ( Boston, MA ), as …

Notice of Annual General Meeting of Orexo | 3/17/2020

… Orexo is aiming to become a leader in the field of substance use disorder. To achieve this, the commercial business will be broadened through business development, M&A and launch of proprietary pharmaceuticals and digital therapies . Orexo’s objectives and strategies onwards is to broaden the US commercial platform to leverage scale and expand sales, further accelerate Orexo US performance and EBIT construction as well as to launch at least one …

Orexo presents sales potential of the pharmaceutical pipeline and digital therapies during the Capital Markets Day | 3/17/2020

Orexo presents sales potential of the pharmaceutical pipeline and digital therapies during the Capital Markets Day Tue, Mar 17, 2020 08:00 CET Uppsala, Sweden – March 17 , 2020. Orexo AB (publ.), today hosts a Capital Market Day in Stockholm, Sweden. On the day the company will present an overview of the company’s growth strategy, pharmaceutical pipeline and digital therapies. In the presentation of the pharmaceutical pipeline the company will present the …

Notice of Annual General Meeting of Orexo - March 16, 2020 | 3/16/2020

… Orexo is aiming to become a leader in the field of substance use disorder. To achieve this, the commercial business will be broadened through business development, M&A and launch of proprietary pharmaceuticals and digital therapies . Orexo’s objectives and strategies onwards is to broaden the US commercial platform to leverage scale and expand sales, further accelerate Orexo US performance and EBIT construction as well as to launch at least one …

Orexo Submits Application for vorvida® to the FDA to Enable Commercialization in the US | PR Newswire | 3/6/2020

… preventable cause of death in the country. Alcohol misuse costs the US about USD 249 billion per year. 4 Dennis Urbaniak , EVP Digital Therapeutics, will provide additional details and comments about the market for digital therapies in the US at the Capital Markets Day March 17, 2020 , in Stockholm, Sweden . At the Capital Markets Day Dr. Mario Weiss , CEO and Founder of GAIA, a global leader in digital therapeutics, will …

Save the date: Orexo to host Capital Markets Day focusing on Digital Health, on March 17, 2020 | 12/3/2019

About Orexo Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs mainly within the growing space of addiction. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercialize its lead product Zubsolv® for treatment of opioid use disorder. Total net sales for 2018 amounted to SEK 783.1 million and the number …

COVID-19

Swedish Pharma company Orexo rolls out digital therapeutic for depression, alcohol use disorder | MobiHealthNews | 7/13/2020

COVID-19 pandemic has created barriers to in-person care, many are pitching technology as a way to help reach individuals in their home. “Due to the COVID-19 pandemic, the need for clinically validated digital therapies is unprecedented. This pressing need, combined with the FDA’s measures to expand availability of digital therapies for psychiatric disorders, have accelerated launch plans for Orexo’s digital offering,” Nikolaj Sørensen, president and CEO of …

Food and Drug Administration

Orexo Launches Deprexis® and Vorvida® in the US and Provides Updated Financial Guidance | PR Newswire | 7/2/2020

digital therapies deprexis ® and vorvida ® , for treatment of symptoms of depression and management of problematic alcohol misuse respectively. deprexis ® is available to patients from July 1 st and vorvida ® from July 15 th . The decision to accelerate the launch is based on the patient need for access to low-risk clinically-validated digital health devices during the ongoing COVID-19 pandemic and the recent US Food and Drug Administration (FDA …

Digital Health

Digital healthcare is all the rage in Covid-19 times. But not everyone is invited to the party | Fortune | 6/17/2020

… version of Term Sheet, Fortune’s newsletter about deals and dealmakers. Sign up here. Venture capital has overflowed with interest in digital health since the pandemic forced patient care into the realm of the bits and … weeks in November, per CNBC —highlighting the issue of integrating digital therapies within the existing hierarchy (think pharmaceutical companies, regulators, and insurers). An important licensing agreement with Otsuka Pharmaceuticals meanwhile fell apart earlier this year …

Digital Therapeutics

Orexo Submits Application for vorvida® to the FDA to Enable Commercialization in the US | PR Newswire | 3/6/2020

… strong clinical evidence, suggests vorvida ® could present an important treatment option for patients.” Dennis Urbaniak , Executive Vice President of Orexo Digital Therapeutics, commented: “Since I joined Orexo in December last year, we have worked intensively … will provide additional details and comments about the market for digital therapies in the US at the Capital Markets Day March 17, 2020 , in Stockholm, Sweden . At the Capital Markets Day Dr. Mario Weiss , CEO …

Mental Health

Highmark Interactive to Launch Therapeutic Trials Using Software to Treat Concussion, Mental Health and More | Globe Newswire | 12/5/2019

English Français Highmark Interactive to Launch Therapeutic Trials Using Software to Treat Concussion, Mental Health and More Their FDA-cleared platform ‘EQ Brain Performance’ currently assists medical professionals in assessment and diagnosis, and now shows … In time, Highmark intends to study the therapeutic benefits of digital therapies for mental health conditions associated with concussion, including major depressive disorder (MDD), ADHD, PTSD and anxiety. The first clinical trials are scheduled to …

Addiction Treatment

Orexo Appoints Dennis Urbaniak as Executive Vice President Digital Health – Company Announcement - FT.com | Financial Times | 12/2/2019

… Health , effective today. Dennis will lead the establishment of Orexo’s global digital health business, initially through the development of two digital therapies, OXD01 (opioid use disorder) and OXD02 (alcohol use disorder), recently licensed from GAIA … innovation. The success of Orexo with Zubsolv® in the opioid addiction treatment market creates a strong and highly synergistic platform to develop and commercialize complementary digital health solutions.” For further information, please contact Orexo AB …

Behavioral Health

Orexo Acquires Exclusive US Rights to Commercialize Vorvida®, a Digital Therapy for Alcohol Use Disorder with Scientifically Proven Efficacy | PR Newswire | 11/27/2019

… to enhance our capabilities in the digital space we will of course leverage our successful commercial infrastructure to make our digital therapies a success in the United States .” Dr. Mario Weiss , CEO and Founder of … safety profiles for digital therapeutics in neuroscience, immunology, oncology, or behavioral health. With more than 140 experts in the field of Medicine, Psychology, Behavioral Medicine, Software Engineering as well as Regulatory and Market Access, GAIA …

Digital Health Market

No one knows how effective digital therapies are, but a new tool from Elektra Labs aims to change that | TechCrunch | 11/12/2019

Depending on which study you believe, the wearable and digital health market could be worth anywhere from $30 billion to nearly $90 billion in the next six years. If the numbers around the size of … industry. It includes the ability to handle adverse events involving digital therapies by providing a single source where problems could be reported; a basic description for consumers of how the products work; an assessment of …

Biometric Monitoring

No one knows how effective digital therapies are, but a new tool from Elektra Labs aims to change that | TechCrunch | 11/12/2019

… the creation of Elektra Labs roughly two years ago. Now the company is launching Atlas , which aims to catalog the biometric monitoring technologies that are flooding the consumer health market. These monitoring technologies, and the … industry. It includes the ability to handle adverse events involving digital therapies by providing a single source where problems could be reported; a basic description for consumers of how the products work; an assessment of …

Big Pharma

No one knows how effective digital therapies are, but a new tool from Elektra Labs aims to change that | TechCrunch | 11/12/2019

… for software-driven products like the atrial fibrillation detection algorithm on the Apple Watch and the ActiGraph activity monitors . And big pharma companies like Roche , Pfizer and Novartis have been investing in these technologies to … industry. It includes the ability to handle adverse events involving digital therapies by providing a single source where problems could be reported; a basic description for consumers of how the products work; an assessment of …

Medication Management

Bayer joins $25M investment in data-driven digital health startup | Becker’s Hospital Review | 11/6/2019

digital therapies specifically to track heart health. The startup has ongoing projects with Johnson & Johnson’s Janssen Pharmaceuticals to develop a digital biomarker for Alzheimer’s disease; it previously partnered with Apple to develop a medication management and adherence Apple Watch app for chemotherapy patients. Medopad is also a member of the Discover-NOW initiative, alongside Google Health, AstraZeneca and IBM, to create the Health Data Research Hub for Real-World Evidence …

Clinical Data

Opinion: Realizing the promise of prescription digital therapeutics | STAT | 10/29/2019

… access treatment when and where they need it. Similar to traditional medicines, PDTs are prescribed by physicians and backed by clinical data and subject to authorization by the Food and Drug Administration. Prescription digital therapeutics … how to create successful FDA submissions. The regulatory pathway for digital therapies is still very much in its infancy and must be tailored for the unique nature of these treatments. The FDA has recognized the …

Health Tech

Opinion: Realizing the promise of prescription digital therapeutics | STAT | 10/29/2019

… care continuum, such as navigating an evolving regulatory space, securing reimbursement, and educating patients and prescribers. Sign up for STAT Health Tech Your weekly guide to how tech is transforming health care and life sciences … how to create successful FDA submissions. The regulatory pathway for digital therapies is still very much in its infancy and must be tailored for the unique nature of these treatments. The FDA has recognized the …

Patient Safety

Opinion: Realizing the promise of prescription digital therapeutics | STAT | 10/29/2019

… also to bring on individuals with the experience and know-how to create successful FDA submissions. The regulatory pathway for digital therapies is still very much in its infancy and must be tailored for the … regulatory pathway for future PDTs while ensuring they meet appropriate patient safety standards. According to the FDA, the experiences gained from this pilot program will “provide more streamlined and efficient regulatory oversight of software-based …

Cognitive Behavioral Therapy

Opinion: Realizing the promise of prescription digital therapeutics | STAT | 10/29/2019

… burden of disease. For example, reSET-O provides patients who are taking medication for opioid-use disorder with instantly accessible cognitive behavioral therapy, which is designed to help patients change for the better the ways … how to create successful FDA submissions. The regulatory pathway for digital therapies is still very much in its infancy and must be tailored for the unique nature of these treatments. The FDA has recognized the …

Elektra Labs

Medtech assessor Elektra Labs is offering free evaluations of COVID-19 biosensors to doctors | TechCrunch | 6/29/2020

Medtech assessor Elektra Labs is offering free evaluations of COVID-19 biosensors to doctors Jonathan Shieber @jshieber / 19 hours As COVID-19 cases in the U.S. continue to spike and doctors and researchers try to … Digital Medicine earlier this year. No one knows how effective digital therapies are, but a new tool from Elektra Labs aims to change that Backed by venture capital firms including Founder Collective, Boost VC, Lux …

Novartis

Digital healthcare is all the rage in Covid-19 times. But not everyone is invited to the party | Fortune | 6/17/2020

Novartis on that pitch (per data from Pitchbook). Earlier this week, the company filed for Chapter 11 bankruptcy protection. Even prior to the onset of the pandemic, the pre-revenue health tech company struggled to raise additional funding and furloughed the majority of its employees for two weeks in November, per CNBC —highlighting the issue of integrating digital therapies within the existing hierarchy (think pharmaceutical companies, regulators, and insurers). An …

WellDoc

WellDoc and Japanese pharma firm Astellas strike a $15 million deal to codevelop a digital therapeutics tool for diabetes in Asia | Business Insider | 11/25/2019

… 15 million payment to the Maryland-based digital therapeutics (DTx) provider to codevelop and commercialize its BlueStar management tool for diabetes in Asia, according to MobiHealthNews. And the duo plans to architect novel digital therapies and get them into the hands of consumers worldwide. Asia-based pharma incumbents are signaling their interest in entering the DTx market — and they’ll likely find success reaching a high volume of digital health-friendly …

Pear Therapeutics

Biofourmis teams up with Novartis to commercialize a digital therapeutics platform for heart failure patients | Business Insider | 11/19/2019

… exacerbations and steer treatments leveraging Biovotion wearables. Previously, Biofourmis was device agnostic, incorporating a variety of wearable tech into its digital therapies — but the buy will afford Biofourmis access to a bevy of new data … month, Novartis subsidiary Sandoz broke off ties with DTx vendor Pear Therapeutics about a year after the duo released an FDA-authorized digital treatment for substance abuse, handing commercialization responsibilities to Pear. This raised questions …

Pfizer

No one knows how effective digital therapies are, but a new tool from Elektra Labs aims to change that | TechCrunch | 11/12/2019

… the atrial fibrillation detection algorithm on the Apple Watch and the ActiGraph activity monitors . And big pharma companies like Roche , Pfizer and Novartis have been investing in these technologies to collect digital biomarker data and … industry. It includes the ability to handle adverse events involving digital therapies by providing a single source where problems could be reported; a basic description for consumers of how the products work; an assessment of …

Akili Interactive

No one knows how effective digital therapies are, but a new tool from Elektra Labs aims to change that | TechCrunch | 11/12/2019

… coding bootcamp and returned to the world she was raised in by taking an internship with the digital therapeutics company Akili Interactive . Coravos always thought she wanted to be in healthcare, but there was one … industry. It includes the ability to handle adverse events involving digital therapies by providing a single source where problems could be reported; a basic description for consumers of how the products work; an assessment of …

Apple Health

No one knows how effective digital therapies are, but a new tool from Elektra Labs aims to change that | TechCrunch | 11/12/2019

… that. The FDA has been accelerating its clearances for software-driven products like the atrial fibrillation detection algorithm on the Apple Watch and the ActiGraph activity monitors . And big pharma companies like Roche , Pfizer and … industry. It includes the ability to handle adverse events involving digital therapies by providing a single source where problems could be reported; a basic description for consumers of how the products work; an assessment of …

Fitbit

No one knows how effective digital therapies are, but a new tool from Elektra Labs aims to change that | TechCrunch | 11/12/2019

… of things it would monitor for the nascent digital therapeutics industry. It includes the ability to handle adverse events involving digital therapies by providing a single source where problems could be reported; a basic description … to get any smaller. As Google’s recent acquisition bid for Fitbit and the company’s reported partnership with Ascension on “Project Nightingale” to collect and digitize more patient data shows, the intersection of technology and healthcare …

Noom

Walmart plans to guide employees to ‘top-performing doctors’ in a bid to cut costs | Business Insider | 10/4/2019

Noom to implement digital therapies for weight management 81% of banking executives see working with partners as the best path to digital transformation Microsoft just announced its foldable phone — here’s why we think the Surface Duo will be its winning smartphone model …

Novo Nordisk

Walmart plans to guide employees to ‘top-performing doctors’ in a bid to cut costs | Business Insider | 10/4/2019

Novo Nordisk is partnering with Noom to implement digital therapies for weight management 81% of banking executives see working with partners as the best path to digital transformation Microsoft just announced its foldable phone — here’s why we think the Surface Duo will be its winning smartphone model …

Big Health

Atrium Health, Cleveland Clinic join latest funding round for startup Xealth | FierceHealthcare | 6/21/2019

… is a growing player in the “digital supply chain” that makes it possible for healthcare providers to prescribe and monitor digital therapies. (Rostislav_Sedlacek) Digital health startup Xealth has raised an additional $3 million in … health and wellness tools. CVS’ platform currently includes one product, Big Health’s Sleepio, a digital tool aimed at improving sleep. “We are already building and executing a digital health formulary,” McSherry said, noting that Xealth’s …

CVS

Atrium Health, Cleveland Clinic join latest funding round for startup Xealth | FierceHealthcare | 6/21/2019

… is a growing player in the “digital supply chain” that makes it possible for healthcare providers to prescribe and monitor digital therapies. (Rostislav_Sedlacek) Digital health startup Xealth has raised an additional $3 million in … funding will be used to further develop the platform. RELATED: CVS launching platform to allow PBM clients to manage supplemental benefit contracts The company is a growing player in what McKesson Ventures executives call the …

CVS Health

Atrium Health, Cleveland Clinic join latest funding round for startup Xealth | FierceHealthcare | 6/21/2019

… is a growing player in the “digital supply chain” that makes it possible for healthcare providers to prescribe and monitor digital therapies. (Rostislav_Sedlacek) Digital health startup Xealth has raised an additional $3 million in … applications and devices for patients. Earlier this month, CVS Caremark, CVS Health’s PBM, unveiled a platform to help its payer clients manage digital health and wellness tools. CVS’ platform currently includes one product, Big Health’s …

Express Scripts

Atrium Health, Cleveland Clinic join latest funding round for startup Xealth | FierceHealthcare | 6/21/2019

… is a growing player in the “digital supply chain” that makes it possible for healthcare providers to prescribe and monitor digital therapies. (Rostislav_Sedlacek) Digital health startup Xealth has raised an additional $3 million in … managers (PBMs) also are moving into this space. Last month, Express Scripts announced plans to launch what the company called the industry’s first digital health formulary, a curated list of applications and devices for patients …

Lux Capital

No one knows how effective digital therapies are, but a new tool from Elektra Labs aims to change that | TechCrunch | 11/12/2019

… of things it would monitor for the nascent digital therapeutics industry. It includes the ability to handle adverse events involving digital therapies by providing a single source where problems could be reported; a basic description … investors, including Maverick Ventures, Arkitekt Ventures, Boost VC, Founder Collective, Lux Capital, SV Angel and Village Global. Alongside several angel investors, including the founders and chief executives from companies including: PillPack, Flatiron Health, National Vision …

No one knows how effective digital therapies are, but a new tool from Elektra Labs aims to change that | Yahoo News | 11/12/2019

… of things it would monitor for the nascent digital therapeutics industry. It includes the ability to handle adverse events involving digital therapies by providing a single source where problems could be reported; a basic description … investors, including Maverick Ventures, Arkitekt Ventures, Boost VC, Founder Collective, Lux Capital, SV Angel and Village Global. Alongside several angel investors, including the founders and chief executives from companies including: PillPack, Flatiron Health, National Vision …

Ascension

WellDoc and Japanese pharma firm Astellas strike a $15 million deal to codevelop a digital therapeutics tool for diabetes in Asia | Business Insider | 11/25/2019

… and commercialize its BlueStar management tool for diabetes in Asia, according to MobiHealthNews. And the duo plans to architect novel digital therapies and get them into the hands of consumers worldwide. Asia-based pharma incumbents … in 2018 by transitioning to value-based agreements Google and Ascension assured doubters their data-sharing venture is HIPAA compliant, but lawmakers still want more details Vodafone is leaning on Google AI for an operations …

No one knows how effective digital therapies are, but a new tool from Elektra Labs aims to change that | TechCrunch | 11/12/2019

… of things it would monitor for the nascent digital therapeutics industry. It includes the ability to handle adverse events involving digital therapies by providing a single source where problems could be reported; a basic description … acquisition bid for Fitbit and the company’s reported partnership with Ascension on “Project Nightingale” to collect and digitize more patient data shows, the intersection of technology and healthcare is a huge opportunity for technology companies …

Humana

WellDoc and Japanese pharma firm Astellas strike a $15 million deal to codevelop a digital therapeutics tool for diabetes in Asia | Business Insider | 11/25/2019

… and commercialize its BlueStar management tool for diabetes in Asia, according to MobiHealthNews. And the duo plans to architect novel digital therapies and get them into the hands of consumers worldwide. Asia-based pharma incumbents … the rest of the story at Business Insider See Also: Humana saved $3.5 billion on Medicare Advantage members in 2018 by transitioning to value-based agreements Google and Ascension assured doubters their data-sharing venture …

Orexo Interim Report Q3 2019 | PR Newswire | 10/24/2019

… and expanding reimbursement to include other products. For Zubsolv, the immediate impact is competition in the previously exclusive contracts, WellCare, Humana and United Health Group. Longer term, Zubsolv will benefit from more payers opening up … therapeutics - increasingly seen as critical to successfully treating opioid addiction. Digital Therapies – an exciting, growing market set to improve patient outcomes The use of digital therapeutics is increasing with digital poised to play a key …

Corey McCann

Opinion: Realizing the promise of prescription digital therapeutics | STAT | 10/29/2019

Realizing the promise of prescription digital therapeutics By Corey McCann October 29, 2019 Alex Hogan/STAT S martphones and tablets have transformed almost every facet of our daily lives, making it nearly impossible to imagine … how to create successful FDA submissions. The regulatory pathway for digital therapies is still very much in its infancy and must be tailored for the unique nature of these treatments. The FDA has recognized the …

Prescription digital therapeutics: reimagining disease treatment- STAT | 10/29/2019

First Opinion Realizing the promise of prescription digital therapeutics By Corey McCann October 29, 2019 Alex Hogan/STAT S martphones and tablets have transformed almost every facet of our daily lives, making it nearly impossible … how to create successful FDA submissions. The regulatory pathway for digital therapies is still very much in its infancy and must be tailored for the unique nature of these treatments. The FDA has recognized the …